Anzeige
Mehr »
Login
Montag, 27.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Der SILBER-STURM kommt - wie diese unterbewertete Firma die Investmentwelt aufmischt und Milliardenwerte hebt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MQNM | ISIN: US46489V1044 | Ticker-Symbol: AAJ
Tradegate
24.05.24
16:35 Uhr
1,500 Euro
+0,120
+8,70 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,3601,40008:38
1,3601,40008:00

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPerspective Therapeutics prices its $80M offering of stock, warrants1
FrPerspective Therapeutics, Inc.: Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants1
FrPerspective Therapeutics files automatic mixed securities shelf1
20.05.Perspective Therapeutics, Inc.: Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 20242
15.05.Perspective Therapeutics GAAP EPS of -$0.02, revenue of $0.33M1
15.05.Perspective Therapeutics, Inc. - 8-K, Current Report1
14.05.Perspective Therapeutics Q1 Earnings Preview2
03.05.Perspective Therapeutics, Inc.: Perspective Therapeutics to Participate at Upcoming May Investor Conferences3
30.04.Perspective Therapeutics, Inc.: Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-a-NET in NETs120SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout...
► Artikel lesen
16.04.Perspective Therapeutics, Inc. - 8-K, Current Report3
08.04.Perspective Therapeutics, Inc. - 8-K, Current Report2
08.04.Perspective Therapeutics, Inc.: Perspective Therapeutics to Participate at Upcoming April Investor Conferences2
01.04.Perspective Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans5
28.03.Perspective Therapeutics, Inc. - 10-K, Annual Report1
28.03.Perspective Therapeutics GAAP EPS of -$0.14, revenue of $1.43M1
28.03.Perspective Therapeutics, Inc. - 8-K, Current Report2
28.03.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results204SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout...
► Artikel lesen
19.03.Perspective Therapeutics, Inc. - 8-K, Current Report4
19.03.Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers320NEW YORK CITY (dpa-AFX) - Radiopharmaceutical company Perspective Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration agreement with Bristol Myers Squibb Co. (BMY) to...
► Artikel lesen
06.03.Perspective Therapeutics, Inc. - 8-K, Current Report4
Seite:  Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1